exatecan mesylate
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma
Conditions
Sarcoma
Trial Timeline
Jan 1, 2003 → Apr 1, 2006
NCT ID
NCT00055939About exatecan mesylate
exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00055939. Target conditions include Sarcoma.
What happened to similar drugs?
1 of 15 similar drugs in Sarcoma were approved
Approved (1) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00055952 | Phase 2 | Completed |
| NCT00055939 | Phase 2 | Completed |
| NCT00017212 | Phase 2 | Completed |
| NCT00005938 | Phase 2 | Completed |
| NCT00004866 | Phase 2 | Completed |
| NCT00004108 | Phase 2 | Completed |
| NCT00004060 | Phase 2 | Completed |
| NCT00004046 | Phase 2 | Completed |
| NCT00003951 | Phase 2 | Completed |
| NCT00004045 | Phase 2 | Completed |
| NCT00004047 | Phase 1 | Completed |
Competing Products
20 competing products in Sarcoma